• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Consumer Staples

The Cure for Alexion

With only one drug on the market, the pharmaceutical company is expanding its pipeline.
By NICHOLAS VARDY
Feb 22, 2012 | 10:30 AM EST
Stocks quotes in this article: ALXN, AAPL

Alexion Pharmaceuticals (ALXN) is niche player in the biotech space, focusing on severe ultra-rare diseases that affect, at most, one out of every 50,000 people.

The Connecticut-based company's emerging business model is to develop drugs for diseases where there is essentially no competition. Soliris, Alexion's only drug on the market to date, is the only drug approved to treat a rare life-threatening blood disorder called paroxysmal nocturnal hemoglobinuria, or PNH, that attacks red blood cells. The monopoly gives Alexion remarkable high pricing power; a year's course of Soliris costs around $400,000.

With sales of Solaris accounting for all of its current business, Alexion is working hard to expand Soliris' label -- that is, the diseases Soliris can be used to treat. In September, the U.S. Food and Drug Administration approved Soliris' to treat a disease called atypical hemolytic uremic syndrome, or aHUS, which causes kidney disease and high blood pressure among children. The European Committee for Medicinal Products for Human Use, or CHMP, also recommends that the same indication be extended to Soliris in Europe.

There was further encouraging news for Alexion recently when Soliris fared well in a mid-stage study that evaluated the drug for yet another indication. The study involved patients suffering from severe and refractory generalized myasthenia gravis, or GMG, which weakens the muscles that control the eyes and eyelids. Encouraged by the positive results, the company intends to evaluate Soliris for this new indication further.

The danger, of course, is that Alexion is just a one-trick pony. After all, it has Solaris but little else.

That's why Alexion is actively expanding its potential drug pipeline, again, focusing on rare diseases that require very expensive drugs to treat. As part of this effort, Alexion recently acquired Enobia Pharma, a company whose primary asset is an enzyme in development to treat hypophosphatasia, or HPP, a genetic disorder that deprives bones of an essential protein, thereby stunting their growth. About one in 100,000 infants are born with HPP. Analysts at Oppenheimer estimate that the drug could take 80% of the global HPP market, with sales reaching $750 million-- essentially the size of Alexion's annual sales of Solaris. The treatment is in Phase 2 trials, with the launch scheduled for the second half of 2014.

From an investment standpoint, Alexion has been a strong stock market performer. It's also developed an Apple (AAPL)-like habit of beating expectations. The stock recently hit a record high after its Feb. 9 earnings announcement beat analysts' fourth-quarter estimates. Revenue rose 46% from a year earlier to $227.6 million, almost $7 million above analysts' views. Earnings rose 58% to $0.41 a share, beating forecasts by $0.07. For the full year, sales rose 45% to $783.4 million, with profit rising 55% to $1.38 a share. For 2012, Alexion sees earnings at $1.60 to $1.70 a share vs. consensus of $1.67. The low end of sales guidance matched views at $1.04 billion, with the high end at $1.07 billion.

Even before Alexion's strong earnings, Goldman Sachs had Alexion on its Conviction Buy list with a $91 price target. After the earnings announcement, Morgan Stanley raised its price target to $96. Robert Baird was even more optimistic, raising its price target to $100 -- 22% above Tuesday's closing price of $81.81.

With Alexion pulling back for four straight days last week, now is a good time to enter the stock. Buy Alexion Pharmaceuticals at market today, and place a stop at $69.50.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Vardy had no positions in the stocks mentioned.

TAGS: Investing | U.S. Equity | Consumer Staples | Healthcare

More from Consumer Staples

McCormick Needs More Spice, It's Fundamentally Flawed

Stephen Guilfoyle
Mar 28, 2023 11:15 AM EDT

Wall Street's ratings have not been very impressive.

Incomparable Costco Is Its Own Competition, But Is the Stock Worth the Price?

Stephen Guilfoyle
Mar 3, 2023 11:55 AM EST

So much more is expected of Costco than its peers.

Procter & Gamble Gains an Upgrade, but Its Charts Have Yet to Turn the Tide

Bruce Kamich
Mar 3, 2023 9:47 AM EST

JP Morgan raises the consumer products giant to an overweight rating, but its shares still aren't displaying much technical vigor.

The Thrill Is Gone at Procter & Gamble: Trade These 2 Stocks Instead

Stephen Guilfoyle
Jan 19, 2023 10:38 AM EST

P&G's sloppy balance sheet is still moving in the wrong direction.

Consumer Discretionary Stocks Are on a Roll as Consumer Staples Suddenly Stumble

Ed Ponsi
Jan 13, 2023 10:00 AM EST

The recent downturn in consumer staples stocks even as the broad market rises could be a positive sign for the economy going forward.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 04:00 PM EDT CHRIS VERSACE

    AAP Podcast: This Solar Company Is a Head-Turner

    Listen to my interview with Brian Roth, CEO of sol...
  • 01:56 PM EDT PETER TCHIR

    Very Cautious

    I am very cautious here. I don't like how the c...
  • 08:58 AM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    How to Adjust Your Trading Style as Market Conditi...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login